Syntex


Laboratorios Syntex SA was a pharmaceutical company formed in Mexico City in 1944 by Russell Marker to manufacture therapeutic steroids from the Mexican yams called cabeza de negro and Barbasco. The demand for barbasco by Syntex initiated the Mexican barbasco trade.
ACS: “In early 1944, the new Mexican company was chartered and named Syntex, S.A.. According to Marker, Somlo was to receive 52% of the shares, Lehmann, 8%, and Marker, 40%, partly in return for his two kilos of progesterone.” Russell Marker, shortly thereafter, left Syntex on account of his ruthless cofounder.
Luis E. Miramontes, George Rosenkranz and Carl Djerassi synthesis of norethindrone, later proven to be an effective pregnancy inhibitor, led to an infusion of capital in Syntex and Mexican steroid pharma industry.George Rosenkranz and Carl Djerassi then went on to synthesizing cortisone from diosgenin, the same phytosteroid contained in Mexican yams used to synthesize progesterone and norethindrone. The synthesis was more economical than the previous Merck & Co. synthesis, which started with bile acids.
Syntex was acquired by the Roche group in 1994.

Prominent researchers

Syntex submitted its compound to a laboratory in Madison, Wisconsin, for biological evaluation, and found it was the most active, orally-effective progestational hormone of its time. Syntex submitted a patent application in November 1951. In August 1953, G.D. Searle & Co. filed for a patent for the synthesis of the double-bond isomer 13 of norethindrone called noretynodrel. Noretynodrel is converted into norethisterone under acidic conditions, such as those in the human stomach, and the new patent did not infringe on the Syntex patent. Searle obtained approval to market noretynodrel before Syntex received its approval. By 1964 three companies, including Syntex, G.D. Searle, and Johnson & Johnson under the Ortho Pharmaceutical brand, were marketing 2-mg doses of the Syntex norethindrone.

Scientific misconduct

Syntex's submission of a fraudulent toxicology analysis of naproxen largely led to the Food and Drug Administration's uncovering of extensive scientific misconduct by Industrial Bio-Test Laboratories in 1976.